Clinical Trials Directory

Trials / Unknown

UnknownNCT02804581

Gum Arabic as Immunomodulator In Rheumatoid Arthritis Patients

Potential Role of Gum Arabic as Immunomodulator In Sudanese Rheumatoid Arthritis Patients

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
45 (estimated)
Sponsor
Lamis Kaddam · Academic / Other
Sex
All
Age
20 Years – 50 Years
Healthy volunteers
Not accepted

Summary

Gum Arabic (GA) rich dietary fiber it is a water-soluble dietary fiber derived from the dried gummy exudates of the stems and branches of Acacia senegal, GA found to have strong immuno modulator in vitro where it increased IL10 production showing strong anti-inflammatory effects (19). The aim of this study is to determine the role of gum Arabic in immunomodulation among patients with rheumatoid arthritis.

Detailed description

Butyrate is short chain fatty acids representing the most important end product of colonic bacterial aerobic fermentation of Gum Arabic , it has a potent anti-inflammatory effect and can down regulates TNF a expression by modulating NF-kB-DNA binding activity , in addition butyrate is known to act as histone deacetylase inhibitor in the cells.Recently, in vitro and in vivo data indicates that HDAC inhibitors may have anti-inflammatory effect due to their effects on cell death acting through acetylation of non-histone proteins. The possible anti-rheumatic mechanisms of HDAC inhibitors, including growth arrest in rheumatoid arthritis synovial fibroblasts (RASFs), suppression of pro-inflammatory cytokines, suppressing angiogenesis as well as the protective effects on bone and cartilage against their destruction. The investigators expect regular intake of GA will raise serum butyrate level. The endogenous butyrate decreases the TNF level. The latter will decrease the number of relapsing episodes, arresting the destruction of joints and improve both survival and life quality of rheumatoid arthritis patients.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTGum ArabicOral intake of GA in powder from30 grams per day

Timeline

Start date
2016-06-01
Primary completion
2016-10-01
Completion
2016-10-01
First posted
2016-06-17
Last updated
2016-06-21

Locations

1 site across 1 country: Sudan

Source: ClinicalTrials.gov record NCT02804581. Inclusion in this directory is not an endorsement.